Pulmonology

In an interview, lead investigator and expert Dr. Martin Kolb discusses his new phase 2b HZN-825 trial and what it's like treating the rare disease.

The reductions were seen as early as week 2 and was sustained throughout the 52 week study.

Dr. Zein speaks of the relationship between eosinophil count and COVID-19 illness and mortality, especially as it related to inhaled corticosteroid use.

Data supporting BI 1015550 as a IPF therapy will be presented at the upcoming ATS meeting.

The esteemed pediatric pulmonologist of Bridge Atlanta Medical Center drops by Lungcast to discuss the disparities that continue to exist in childhood asthma.

Patients with asthma and bronchiectasis were more likely to have chronic rhinosinusitis than patients without bronchiectasis, according to investigators.

The renowned expert joins to discuss the clinical characteristics, societal burdens, and promising therapy research surrounding the hematologic disease.

New data from the NAVIGATOR study found that tezepelumab was associated with fewer asthma exacerbations throughout all seasons of the year compared to placebo.

Though continuous positive airway pressure and high-flow nasal oxygen have both been recommended for acute hypoxemic respiratory failure in patients infected with the COVID-19 virus, the effectiveness and safety of these strategies were uncertain.

Despite the prevalence of pulmonary exacerbations in patients with cystic fibrosis, there is no standardized definition to diagnose these events in affected patients.

A better understanding of this connection could yield preventative treatments.

Take a Break was a 3-week interactive experience that involved motivational text messages, challenge quizzes, brief goal setting and more.

The institute will assemble and support a diverse, multidisciplinary team of scientists and researchers to lead the charge breakthroughs in airway science.

The selective inhibitor therapy is being investigated for the treatment of 2 forms of chronic cough—an indication that's been unmet in 60 years.

The Temple-based investigator and expert joins Lungcast to review recent clinical trials, recommendations and non-surgical techniques for patients who have advanced COPD.

Preconception paternal smoking was also not associated with birth weight or paternal BMI.

Patients with asthma were at increased risk of hospitalization and ICU admission or death, prompting investigators to suggest these patients be considered a priority group for booster COVID-19 vaccines.

Data from a recent Chinese cohort study supported the development of dietary guidelines specific to obstructive sleep apnea.

Patients with severe eosinophilic asthma who stopped treatment also experienced reduced asthma control and shorter times for clinically significant exacerbations.

Dr. Siddharthan speaks of high COPD rates in low- and middle-income countries with increased environmental exposures and a lack of diagnostic tools.

The newest venture from Mount Sinai is intended to build a pipeline of physician-scientists.

More than 70% of parents of children with asthma said they in favor of the influenza vaccine during the COVID-19 pandemic.

The discriminative accuracy of the 3 instruments were evaluated in low- and middle-income settings in Nepal, Peru, and Uganda, with further research needed to determine whether implementation is associated with improved clinical outcomes.

Investigators concluded that long-term data are needed regarding surgery, but confirmed it to be more efficacious than medical therapy alone.

Investigators report exposure to fine particulate matter in 2019 exceeded the World Health Organization guideline limit.

Dr. Al Rizzo highlights the best insights and opinions from featured guests this last year.

Steven D. Nathan, MD, FCCP, and Fernando J. Martinez, MD, MS, share clinical pearls and advice for the management of IPF.

Expert pulmonologists comment on emerging therapies in the pipeline for the treatment of IPF.

Fernando J. Martinez, MD, MS, and Steven D. Nathan, MD, FCCP, share their personal experiences using pirfenidone and nintedanib in clinical practice and discuss the role of managing comorbidities for the treatment of IPF.